AR071159A1 - Derivados de purina, composiciones farmaceuticas y usos - Google Patents
Derivados de purina, composiciones farmaceuticas y usosInfo
- Publication number
- AR071159A1 AR071159A1 ARP090100607A ARP090100607A AR071159A1 AR 071159 A1 AR071159 A1 AR 071159A1 AR P090100607 A ARP090100607 A AR P090100607A AR P090100607 A ARP090100607 A AR P090100607A AR 071159 A1 AR071159 A1 AR 071159A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- amino acid
- arylalkyl
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 amino acid ester Chemical class 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000007970 thio esters Chemical class 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plasma & Fusion (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto que tiene la estructura (1) en la cual Y es independientemente -OR3, un aminoácido, amida de aminoácido o ester de aminoácido o tioéster de aminoácido ligado por un grupo amino del aminoácido; R1 es CH3 o H; R2' y R2 son independientemente H, halo, NH2, NH(R10), N(R10)2 o X, aunque por lo menos un R2 o R2' es X; R3 es independientemente H; arilo no sustituido, heterociclo, alquilo C1-12, alquenilo C2-12 o alquinilo C2-12; o bien arilo, heterociclo, alquilo C1-12, alquenilo C2-12 o alquinilo C2-12 sustituido con alcoxi C1-12, halo, carboxilo, carboxiléster, hidroxilo, amino, CN, NO2, OH, tiol, tioléster, azido, arilamino, haloalquilo C1-12 (1-6 átomos de halogeno), alquenilo C2-12 o alquinilo C2-12; X es -OR10, R10 es alquilo C1-15 no sustituido, alquenilo C2-15, arilalquenilo C6-15, arilalquinilo C6-15, alquinilo C2-15, alquilamino C1-6-alquilo C1-6-, aralquilo C5-15, heteroaralquilo C6-15, arilo C5-6, heterocicloalquilo C2-6; o alquilo C2-15, alquenilo C3-15, arilalquenilo C6-15, alquinilo C3-15, arilalquinilo C7-15, alquilamino C1-6-alquilo C1-6-, aralquilo C5-15, heteroalquilo C6-15 o heterocicloalquilo C3-6 donde 1 a 2 grupos metileno del resto alquilo no adyacente al oxígeno de -OR10 han sido reemplazados con -O-, -S- o N(R3); o uno de los mencionados grupos R10 que está sustituido con 1 a 3 de halo, R3, CN o N3; Z es N o CH, siempre que el nucleo heterocíclico varíe con respecto a la purina en no más de un Z; y las sales aceptables para uso terapéutico y/o isomeros opticos enriquecidos del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3014808P | 2008-02-20 | 2008-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071159A1 true AR071159A1 (es) | 2010-06-02 |
Family
ID=40532651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100607A AR071159A1 (es) | 2008-02-20 | 2009-02-20 | Derivados de purina, composiciones farmaceuticas y usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8163718B2 (es) |
| EP (2) | EP2245037B1 (es) |
| JP (2) | JP5588356B2 (es) |
| KR (2) | KR101728647B1 (es) |
| CN (2) | CN105753905A (es) |
| AR (1) | AR071159A1 (es) |
| AU (3) | AU2009215547B2 (es) |
| CA (1) | CA2715885C (es) |
| CY (2) | CY1115571T1 (es) |
| DK (2) | DK2245037T3 (es) |
| ES (2) | ES2529209T3 (es) |
| HK (2) | HK1150313A1 (es) |
| HR (2) | HRP20140895T1 (es) |
| NZ (1) | NZ587464A (es) |
| PL (2) | PL2245037T4 (es) |
| PT (2) | PT2245037E (es) |
| SI (2) | SI2245037T1 (es) |
| TW (1) | TWI444384B (es) |
| WO (1) | WO2009105513A2 (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| US20080032960A1 (en) | 2006-04-04 | 2008-02-07 | Regents Of The University Of California | PI3 kinase antagonists |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| NZ613219A (en) | 2008-01-04 | 2014-11-28 | Intellikine Llc | Heterocyclic containing entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| AU2009305669A1 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2010079833A1 (ja) | 2009-01-08 | 2010-07-15 | 株式会社癌免疫研究所 | 新規癌抗原ｅＥＦ２ |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| CN102093422B (zh) | 2009-12-10 | 2015-02-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 无环核苷膦酸酯衍生物及其医药用途 |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
| CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20141371A1 (es) | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| EP2751112B1 (en) | 2011-09-02 | 2019-10-09 | The Regents of The University of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| CA2752008A1 (en) | 2011-09-13 | 2013-03-13 | Universite De Montreal | Combination therapy using ribavirin as elf4e inhibitor |
| ES2734495T3 (es) | 2011-12-22 | 2019-12-10 | Geron Corp | Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１の調節 |
| US9889180B2 (en) | 2012-11-19 | 2018-02-13 | Agency For Science, Technology And Research | Method of treating cancer |
| EP2931738B1 (en) * | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| BR112015023705A8 (pt) | 2013-03-15 | 2020-03-17 | Univ California | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
| CN104558035B (zh) * | 2013-10-22 | 2017-12-19 | 连云港恒运药业有限公司 | 一种替诺福韦前药的纯化方法 |
| DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| PL3194411T3 (pl) * | 2014-09-15 | 2022-06-20 | The Regents Of The University Of California | Analogi nukleotydów |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| KR20170123308A (ko) | 2014-12-26 | 2017-11-07 | 에모리 유니버시티 | Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
| MY192607A (en) * | 2015-08-10 | 2022-08-29 | Merck Sharp & Dohme | Antiviral beta-amino acid ester phosphodiamide compounds |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| EP3386512B1 (en) * | 2015-12-10 | 2023-11-22 | Merck Sharp & Dohme LLC | Antiviral phosphodiamide prodrugs of tenofovir |
| WO2017106069A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017191297A1 (en) * | 2016-05-04 | 2017-11-09 | Bci Pharma | Adenine derivatives as protein kinase inhibitors |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20190033526A (ko) | 2016-06-24 | 2019-03-29 | 인피니티 파마슈티칼스, 인코포레이티드 | 병용 요법 |
| WO2018080903A1 (en) | 2016-10-26 | 2018-05-03 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| MX2019007262A (es) | 2016-12-22 | 2019-09-05 | Merck Sharp & Dohme | Compuestos antivirales de bencilamina fosfodiamida. |
| KR20190100250A (ko) | 2016-12-22 | 2019-08-28 | 머크 샤프 앤드 돔 코포레이션 | 테노포비르의 항바이러스 지방족 에스테르 전구약물 |
| BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
| CN108096562B (zh) * | 2017-12-25 | 2021-05-11 | 武汉百药联科科技有限公司 | 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途 |
| US11826375B2 (en) | 2018-07-19 | 2023-11-28 | Merck Sharp & Dohme Llc | Phosphinic amide prodrugs of tenofovir |
| CN112778363B (zh) * | 2019-11-05 | 2024-03-15 | 华创合成制药股份有限公司 | 一种硝基咪唑类唑衍生物及其制备方法和用途 |
| EP4337667A1 (en) * | 2022-07-21 | 2024-03-20 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617457A1 (de) * | 1966-12-16 | 1972-04-20 | Erba Carlo Spa | Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte |
| US3665838A (en) * | 1970-01-29 | 1972-05-30 | Wilson Lighting Ltd | Air chamber assembly |
| CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| DE3580384D1 (de) | 1984-04-09 | 1990-12-13 | Toyo Boseki | Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle. |
| CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US5141752A (en) | 1986-05-09 | 1992-08-25 | Alza Corporation | Delayed drug delivery device |
| CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| IL84477A (en) | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| US5459256A (en) | 1987-04-17 | 1995-10-17 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Lipophilic, aminohydrolase-activated prodrugs |
| GB8802142D0 (en) * | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
| CA2001715C (en) | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
| US5098443A (en) | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| CA2479846C (en) | 1989-05-15 | 2007-07-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Phosphonomethoxymethylpurine/pyrimidine derivatives |
| PT95516A (pt) | 1989-10-06 | 1991-08-14 | Wellcome Found | Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos |
| MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| US5302585A (en) | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| SK280313B6 (sk) | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
| JPH05509307A (ja) | 1990-07-19 | 1993-12-22 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | プリンの抗ウイルス性ホスホノ―アルケン誘導体 |
| EP0468119A1 (en) | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US5208221A (en) | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| CZ284678B6 (cs) | 1991-05-20 | 1999-01-13 | Ústav Organické Chemie A Biochemie Avčr | Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití |
| WO1993007157A1 (en) | 1991-10-11 | 1993-04-15 | Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic | Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| DE4308096A1 (de) | 1993-03-13 | 1994-09-15 | Hoechst Ag | Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung |
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| CA2126601A1 (en) * | 1993-06-29 | 1994-12-30 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
| JP4086314B2 (ja) | 1993-09-17 | 2008-05-14 | ギリアード サイエンシーズ， インコーポレイテッド | ヌクレオチドアナログ |
| WO1995026734A1 (en) | 1994-04-04 | 1995-10-12 | Freeman William R | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
| FR2723740B1 (fr) * | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| IL120202A (en) * | 1996-03-07 | 2001-03-19 | Akzo Nobel Nv | Container with freeze-dried vaccine components |
| US20030072814A1 (en) | 1999-12-16 | 2003-04-17 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of warts |
| CZ20022353A3 (cs) | 2000-01-07 | 2003-02-12 | Universitaire Instelling Antwerpen | Deriváty purinu, způsob jejich přípravy a jejich použití |
| KR100767432B1 (ko) | 2000-07-21 | 2007-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법 |
| FR2862306B1 (fr) * | 2003-11-17 | 2008-05-30 | Aventis Pasteur | Composition vaccinale |
| EP1716162B1 (en) * | 2003-12-30 | 2010-08-18 | Gilead Sciences, Inc. | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
| AU2005263465B2 (en) * | 2004-07-23 | 2010-07-29 | Bayer Healthcare Llc | Sterile freezing, drying, storing, assaying and filling process (SFD-SAF process) (pellet freeze-drying process for parenteral biopharmaceuticals) |
| US20060165717A1 (en) * | 2005-01-25 | 2006-07-27 | Sanofi Pasteur | DCchol in newborns |
| WO2007002912A2 (en) | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Anti-proliferative compounds, compositions, and methods of use thereof |
| WO2007002808A1 (en) | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof |
| WO2007136650A2 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
| US9521854B2 (en) * | 2006-05-31 | 2016-12-20 | Air Liquide Industrial U.S. Lp | Method and device for creating frozen pellets of a foodstuff |
| ES2437871T3 (es) * | 2006-07-07 | 2014-01-14 | Gilead Sciences, Inc. | Moduladores del receptor tipo toll 7 |
| CN101066981B (zh) * | 2007-05-25 | 2011-10-05 | 中国科学院上海药物研究所 | 非环核苷膦酸酯类化合物及其组合物、制备方法和用途 |
-
2009
- 2009-02-16 TW TW098104834A patent/TWI444384B/zh active
- 2009-02-19 SI SI200931021T patent/SI2245037T1/sl unknown
- 2009-02-19 PL PL09712645T patent/PL2245037T4/pl unknown
- 2009-02-19 AU AU2009215547A patent/AU2009215547B2/en active Active
- 2009-02-19 CA CA2715885A patent/CA2715885C/en active Active
- 2009-02-19 CN CN201610086843.7A patent/CN105753905A/zh active Pending
- 2009-02-19 PL PL11151008T patent/PL2308885T3/pl unknown
- 2009-02-19 DK DK09712645.2T patent/DK2245037T3/da active
- 2009-02-19 PT PT97126452T patent/PT2245037E/pt unknown
- 2009-02-19 KR KR1020167009014A patent/KR101728647B1/ko active IP Right Grant
- 2009-02-19 JP JP2010547740A patent/JP5588356B2/ja active Active
- 2009-02-19 WO PCT/US2009/034471 patent/WO2009105513A2/en active Application Filing
- 2009-02-19 CN CN200980113907.6A patent/CN102015739B/zh active Active
- 2009-02-19 NZ NZ587464A patent/NZ587464A/en unknown
- 2009-02-19 KR KR1020107021189A patent/KR101612138B1/ko active IP Right Grant
- 2009-02-19 US US12/388,789 patent/US8163718B2/en active Active
- 2009-02-19 DK DK11151008.7T patent/DK2308885T3/da active
- 2009-02-19 ES ES11151008.7T patent/ES2529209T3/es active Active
- 2009-02-19 SI SI200931104T patent/SI2308885T1/sl unknown
- 2009-02-19 PT PT111510087T patent/PT2308885E/pt unknown
- 2009-02-19 ES ES09712645.2T patent/ES2516715T3/es active Active
- 2009-02-19 EP EP09712645.2A patent/EP2245037B1/en active Active
- 2009-02-19 EP EP11151008.7A patent/EP2308885B1/en active Active
- 2009-02-20 AR ARP090100607A patent/AR071159A1/es active IP Right Grant
-
2011
- 2011-05-03 HK HK11104417A patent/HK1150313A1/xx unknown
- 2011-10-12 HK HK11110815.9A patent/HK1156631A1/xx unknown
-
2014
- 2014-01-06 JP JP2014000324A patent/JP2014088416A/ja not_active Withdrawn
- 2014-07-10 AU AU2014203786A patent/AU2014203786B2/en active Active
- 2014-09-18 CY CY20141100761T patent/CY1115571T1/el unknown
- 2014-09-18 HR HRP20140895AT patent/HRP20140895T1/hr unknown
-
2015
- 2015-01-07 HR HRP20150005TT patent/HRP20150005T1/hr unknown
- 2015-01-30 CY CY20151100102T patent/CY1116015T1/el unknown
-
2016
- 2016-10-28 AU AU2016250468A patent/AU2016250468A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071159A1 (es) | Derivados de purina, composiciones farmaceuticas y usos | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR069464A1 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| CO6180441A2 (es) | Inhibidores nucleosidos del hcv | |
| AR060618A1 (es) | Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| AR047382A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| CY1114906T1 (el) | Νεα παραγωγα 6-τριαζολοπυριδαζινο-σουλφανυλο βενζοθειαζολης και βενζιμιδαζολης, η διαδικασια της παρασκευης τους, η εφαρμογη τους ως φαρμακα, φαρμακευτικες συνθεσεις και νεα χρηση κυριως ως αναστολεις του μετ | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR078674A1 (es) | Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas | |
| AR079510A1 (es) | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| PE20071229A1 (es) | Procesos para la sintesis convergente de los derivados de caliqueamicida | |
| BR112014008934A2 (pt) | composição, método de obtenção da composição e formulação fitossanitária que a compreende | |
| AR084251A1 (es) | Inhibidores dimericos de las iap | |
| BRPI1016069A8 (pt) | Misturas de ésteres e composições compreendendo tais misturas de ésteres | |
| AR054266A1 (es) | Indoles sustituidos con piperidina | |
| CO6320143A1 (es) | Nuevos derivados dihidroindolonas su procedimeinto de preparacion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |